glp 1 deficiency Impact of GLP- Receptor Agonist Therapy in Patients High Risk for Sarcopenia | Current Nutrition Reports Nutritional Deficiencies with weekly GLP-1

Amycretin, Novo Nordisks oral dual GLP-1/amylin agonist, showed 13% weight loss in early trials, signaling a move toward multi-pathway oral therapies

doi: 10.1073/pnas.0406458102 151 BoyleMPKolberBJVogtSKWozniakDFMugliaLJ

While findings are promising, more human studies are needed to better understand its full effects and long-term benefits

Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ